vs
ALBANY INTERNATIONAL CORP（AIN）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
ALBANY INTERNATIONAL CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$321.2M vs $199.9M），ALBANY INTERNATIONAL CORP净利率更高（4.3% vs -29.5%，领先33.8%），ALBANY INTERNATIONAL CORP同比增速更快（12.0% vs -5.9%），ALBANY INTERNATIONAL CORP自由现金流更多（$51.4M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.2%）
奥尔巴尼国际是全球先进材料与工业技术企业，下设两大核心业务板块：为造纸等工业生产提供定制工程织物的机械织物部门，以及为航空航天、国防领域研发高性能复合材料部件的工程复合材料部门，业务覆盖全球多个区域。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
AIN vs APLS — 直观对比
营收规模更大
AIN
是对方的1.6倍
$199.9M
营收增速更快
AIN
高出17.9%
-5.9%
净利率更高
AIN
高出33.8%
-29.5%
自由现金流更多
AIN
多$65.7M
$-14.3M
两年增速更快
APLS
近两年复合增速
1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $321.2M | $199.9M |
| 净利润 | $13.9M | $-59.0M |
| 毛利率 | 31.1% | — |
| 营业利润率 | 9.3% | -25.6% |
| 净利率 | 4.3% | -29.5% |
| 营收同比 | 12.0% | -5.9% |
| 净利润同比 | -21.5% | -62.2% |
| 每股收益（稀释后） | $0.56 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AINAPLS
| Q4 25 | $321.2M | $199.9M | ||
| Q3 25 | $261.4M | $458.6M | ||
| Q2 25 | $311.4M | $178.5M | ||
| Q1 25 | $288.8M | $166.8M | ||
| Q4 24 | $286.9M | $212.5M | ||
| Q3 24 | $298.4M | $196.8M | ||
| Q2 24 | $332.0M | $199.7M | ||
| Q1 24 | $313.3M | $172.3M |
净利润AINAPLS
| Q4 25 | $13.9M | $-59.0M | ||
| Q3 25 | $-97.8M | $215.7M | ||
| Q2 25 | $9.2M | $-42.2M | ||
| Q1 25 | $17.4M | $-92.2M | ||
| Q4 24 | $17.7M | $-36.4M | ||
| Q3 24 | $18.0M | $-57.4M | ||
| Q2 24 | $24.6M | $-37.7M | ||
| Q1 24 | $27.3M | $-66.4M |
毛利率AINAPLS
| Q4 25 | 31.1% | — | ||
| Q3 25 | -19.1% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 33.4% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 30.3% | — | ||
| Q2 24 | 33.9% | — | ||
| Q1 24 | 34.7% | — |
营业利润率AINAPLS
| Q4 25 | 9.3% | -25.6% | ||
| Q3 25 | -44.6% | 48.7% | ||
| Q2 25 | 7.2% | -18.6% | ||
| Q1 25 | 9.8% | -50.0% | ||
| Q4 24 | 8.5% | -12.3% | ||
| Q3 24 | 8.4% | -24.0% | ||
| Q2 24 | 12.9% | -14.7% | ||
| Q1 24 | 12.4% | -36.0% |
净利率AINAPLS
| Q4 25 | 4.3% | -29.5% | ||
| Q3 25 | -37.4% | 47.0% | ||
| Q2 25 | 2.9% | -23.6% | ||
| Q1 25 | 6.0% | -55.3% | ||
| Q4 24 | 6.2% | -17.1% | ||
| Q3 24 | 6.0% | -29.2% | ||
| Q2 24 | 7.4% | -18.9% | ||
| Q1 24 | 8.7% | -38.5% |
每股收益（稀释后）AINAPLS
| Q4 25 | $0.56 | $-0.40 | ||
| Q3 25 | $-3.37 | $1.67 | ||
| Q2 25 | $0.31 | $-0.33 | ||
| Q1 25 | $0.56 | $-0.74 | ||
| Q4 24 | $0.57 | $-0.30 | ||
| Q3 24 | $0.57 | $-0.46 | ||
| Q2 24 | $0.79 | $-0.30 | ||
| Q1 24 | $0.87 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $112.3M | $466.2M |
| 总债务越低越好 | $455.7M | — |
| 股东权益账面价值 | $726.2M | $370.1M |
| 总资产 | $1.7B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.63× | — |
8季度趋势，按日历期对齐
现金及短期投资AINAPLS
| Q4 25 | $112.3M | $466.2M | ||
| Q3 25 | $108.3M | $479.2M | ||
| Q2 25 | $106.7M | $370.0M | ||
| Q1 25 | $119.4M | $358.4M | ||
| Q4 24 | $115.3M | $411.3M | ||
| Q3 24 | $127.2M | $396.9M | ||
| Q2 24 | $116.4M | $360.1M | ||
| Q1 24 | $125.4M | $325.9M |
总债务AINAPLS
| Q4 25 | $455.7M | — | ||
| Q3 25 | $480.6M | — | ||
| Q2 25 | $444.7M | — | ||
| Q1 25 | $416.4M | — | ||
| Q4 24 | $318.5M | — | ||
| Q3 24 | $362.2M | — | ||
| Q2 24 | $377.1M | — | ||
| Q1 24 | $439.1M | $93.1M |
股东权益AINAPLS
| Q4 25 | $726.2M | $370.1M | ||
| Q3 25 | $739.3M | $401.2M | ||
| Q2 25 | $888.6M | $156.3M | ||
| Q1 25 | $900.0M | $164.2M | ||
| Q4 24 | $943.5M | $228.5M | ||
| Q3 24 | $991.0M | $237.1M | ||
| Q2 24 | $967.5M | $264.3M | ||
| Q1 24 | $967.5M | $266.7M |
总资产AINAPLS
| Q4 25 | $1.7B | $1.1B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.7B | $821.4M | ||
| Q1 25 | $1.7B | $807.3M | ||
| Q4 24 | $1.6B | $885.1M | ||
| Q3 24 | $1.8B | $901.9M | ||
| Q2 24 | $1.8B | $904.5M | ||
| Q1 24 | $1.8B | $831.9M |
负债/权益比AINAPLS
| Q4 25 | 0.63× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — | ||
| Q1 24 | 0.45× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $73.7M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $51.4M | $-14.3M |
| 自由现金流率自由现金流/营收 | 16.0% | -7.1% |
| 资本支出强度资本支出/营收 | 6.9% | 0.1% |
| 现金转化率经营现金流/净利润 | 5.31× | — |
| 过去12个月自由现金流最近4个季度 | $82.6M | $45.0M |
8季度趋势，按日历期对齐
经营现金流AINAPLS
| Q4 25 | $73.7M | $-14.2M | ||
| Q3 25 | $43.9M | $108.5M | ||
| Q2 25 | $32.7M | $4.4M | ||
| Q1 25 | $2.1M | $-53.4M | ||
| Q4 24 | $78.5M | $19.4M | ||
| Q3 24 | $47.0M | $34.1M | ||
| Q2 24 | $83.4M | $-8.3M | ||
| Q1 24 | $9.6M | $-133.0M |
自由现金流AINAPLS
| Q4 25 | $51.4M | $-14.3M | ||
| Q3 25 | $25.9M | $108.3M | ||
| Q2 25 | $18.8M | $4.4M | ||
| Q1 25 | $-13.5M | $-53.4M | ||
| Q4 24 | $60.2M | $19.3M | ||
| Q3 24 | $31.6M | — | ||
| Q2 24 | $63.6M | $-8.4M | ||
| Q1 24 | $-17.3M | $-133.3M |
自由现金流率AINAPLS
| Q4 25 | 16.0% | -7.1% | ||
| Q3 25 | 9.9% | 23.6% | ||
| Q2 25 | 6.0% | 2.5% | ||
| Q1 25 | -4.7% | -32.0% | ||
| Q4 24 | 21.0% | 9.1% | ||
| Q3 24 | 10.6% | — | ||
| Q2 24 | 19.2% | -4.2% | ||
| Q1 24 | -5.5% | -77.3% |
资本支出强度AINAPLS
| Q4 25 | 6.9% | 0.1% | ||
| Q3 25 | 6.9% | 0.0% | ||
| Q2 25 | 4.5% | 0.0% | ||
| Q1 25 | 5.4% | 0.0% | ||
| Q4 24 | 6.4% | 0.0% | ||
| Q3 24 | 5.2% | 0.0% | ||
| Q2 24 | 6.0% | 0.0% | ||
| Q1 24 | 8.6% | 0.2% |
现金转化率AINAPLS
| Q4 25 | 5.31× | — | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 4.44× | — | ||
| Q3 24 | 2.61× | — | ||
| Q2 24 | 3.39× | — | ||
| Q1 24 | 0.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
